24 Jun Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.
Posted at 00:00h
in
Authored by: Bruyand Mathias, Ryom Lene, Shepherd Leah, Fatkenheuer Gerd, Grulich Andrew, Reiss Peter, de Wit Stéphane, D Arminio Monforte Antonella, Furrer Hansjakob, Pradier Christian, Lundgren Jens, Sabin Caroline
In: JAIDS‑JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 68(5), 2015, p.568‑577.
http://www.ncbi.nlm.nih.gov/pubmed/25763785